MA29437B1 - Compose d'imidazopyridazine - Google Patents

Compose d'imidazopyridazine

Info

Publication number
MA29437B1
MA29437B1 MA30307A MA30307A MA29437B1 MA 29437 B1 MA29437 B1 MA 29437B1 MA 30307 A MA30307 A MA 30307A MA 30307 A MA30307 A MA 30307A MA 29437 B1 MA29437 B1 MA 29437B1
Authority
MA
Morocco
Prior art keywords
compounds
imidazopyridazine compound
imidazopyridazine
compound
crf1
Prior art date
Application number
MA30307A
Other languages
English (en)
Inventor
Heather Janelle Barbosa
Elizabeth Aaron Collins
Chafiq Hamdouchi
Erik James Hembre
Philip Arthur Hipskind
Richard Duane Johnston
Jianliang Lu
Michael John Rupp
Takako Takakuwa
Richard Craig Thompson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA29437B1 publication Critical patent/MA29437B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Transplantation (AREA)

Abstract

L'INVENTION CONCERNE DE NOUVEAUX COMPOSÉS D'IMIDAZO[1,2-B]PYRIDAZINE SUBSTITUÉS DE LA FORMULE I: DES COMPOSITIONS PHARMACEUTIQUES ASSOCIÉES DE LA FORMULE I, AINSI QUE L'UTILISATION DE CES COMPOSÉS COMME ANTAGONISTES DU RÉCEPTEUR DU FACTEUR 1 DE LIBÉRATION DE LA CORTICOTROPHINE (CRF1) LORS DU TRAITEMENT DE TROUBLES PSYCHIATRIQUES ET DE MALADIES NEUROLOGIQUES.
MA30307A 2005-03-21 2007-10-19 Compose d'imidazopyridazine MA29437B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US66381605P 2005-03-21 2005-03-21

Publications (1)

Publication Number Publication Date
MA29437B1 true MA29437B1 (fr) 2008-05-02

Family

ID=36753943

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30307A MA29437B1 (fr) 2005-03-21 2007-10-19 Compose d'imidazopyridazine

Country Status (25)

Country Link
US (1) US7612067B2 (fr)
EP (1) EP1869049B1 (fr)
JP (1) JP4971300B2 (fr)
KR (1) KR20070120963A (fr)
CN (1) CN101142217B (fr)
AT (1) ATE424402T1 (fr)
AU (1) AU2006227300B2 (fr)
BR (1) BRPI0608857A2 (fr)
CA (1) CA2600478C (fr)
CR (1) CR9389A (fr)
CY (1) CY1109069T1 (fr)
DE (1) DE602006005477D1 (fr)
DK (1) DK1869049T3 (fr)
EA (1) EA012393B1 (fr)
ES (1) ES2321446T3 (fr)
IL (1) IL185014A0 (fr)
MA (1) MA29437B1 (fr)
MX (1) MX2007011600A (fr)
NO (1) NO20074961L (fr)
PL (1) PL1869049T3 (fr)
PT (1) PT1869049E (fr)
SI (1) SI1869049T1 (fr)
TN (1) TNSN07358A1 (fr)
WO (1) WO2006102194A1 (fr)
ZA (1) ZA200706715B (fr)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
SI2044025T1 (sl) 2006-06-30 2013-01-31 Novartis Ag Kinolinonski derivati in njihovi farmacevtski sestavki
EP2076515B1 (fr) * 2006-09-20 2013-07-17 Eli Lilly And Company Composés de thiophène pyrazolopyrimidine
JP5090528B2 (ja) 2007-07-26 2012-12-05 ノバルティス アーゲー ＡＬＫ４またはＡＬＫ５が介在する疾患を処置するための２、３、７位置換イミダゾ［１，２−ｂ］ピリダジン類
BRPI0822240A2 (pt) * 2007-12-21 2015-06-30 Wyeth Llc Composto imidazo [1,2-b] piridazina como moduladores de receptores x hepáticos
EP2250160B1 (fr) 2008-01-25 2015-11-11 Millennium Pharmaceuticals, Inc. Dérivés de thiophène et leur utilisation comme inhibiteurs de phosphatidylinositol 3-kinase (pi3k)
JP5394404B2 (ja) 2008-02-06 2014-01-22 ブリストル−マイヤーズ スクイブ カンパニー キナーゼ阻害剤として有用な置換イミダゾピリダジン類
EP2350075B1 (fr) 2008-09-22 2014-03-05 Array Biopharma, Inc. Composés imidazo[1,2b]pyridazine substitués comme inhibiteurs de kinases trk
HUE057625T2 (hu) 2008-10-22 2022-05-28 Array Biopharma Inc TRK kináz inhibitor szubsztituált pirazolo[1,5-a]pirimidin vegyületek
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
CA2750935A1 (fr) * 2009-01-30 2010-08-12 Millennium Pharmaceuticals, Inc. Heteroaryles et applications associees
US8796314B2 (en) 2009-01-30 2014-08-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
NZ599549A (en) * 2009-10-26 2013-11-29 Signal Pharm Llc Methods of synthesis and purification of heteroaryl compounds
US20120220581A1 (en) * 2009-10-30 2012-08-30 Janssen-Cilag, S.A. IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
CN101830909A (zh) * 2010-04-26 2010-09-15 西安近代化学研究所 4氢-环戊[2,1-b;3,4-b′]双噻吩酮的制备方法
WO2011146336A1 (fr) 2010-05-20 2011-11-24 Array Biopharma Inc. Composés macrocycliques en tant qu'inhibiteurs de kinase trk
WO2012021615A1 (fr) 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Hétéroaryles et utilisations
PE20131304A1 (es) 2010-08-11 2013-11-14 Millennium Pharm Inc Heteroarilos y sus usos
WO2012021611A1 (fr) 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Hétéroaryles et utilisations de ceux-ci
TW201307309A (zh) 2010-10-13 2013-02-16 Millennium Pharm Inc 雜芳基化合物及其用途
DE102011075398A1 (de) * 2011-05-06 2012-11-08 Bayer Pharma Aktiengesellschaft Substituierte Imidazopyridazine und ihre Verwendung
CA2838645C (fr) 2011-06-27 2020-03-10 Janssen Pharmaceutica Nv Derives de 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline
KR20140095513A (ko) * 2011-11-01 2014-08-01 에프. 호프만-라 로슈 아게 이미다조피리다진 화합물
US9669035B2 (en) 2012-06-26 2017-06-06 Janssen Pharmaceutica Nv Combinations comprising PDE 2 inhibitors such as 1-aryl-4-methyl-[1,2,4]triazolo-[4,3-A]]quinoxaline compounds and PDE 10 inhibitors for use in the treatment of neurological of metabolic disorders
ES2607184T3 (es) 2012-07-09 2017-03-29 Janssen Pharmaceutica, N.V. Inhibidores de la enzima fosfodiesterasa 10
WO2014095381A1 (fr) 2012-12-19 2014-06-26 Basf Se Composés imidazolyl et triazolyl fongicides
EP2746279A1 (fr) 2012-12-19 2014-06-25 Basf Se Composés triazolyles et imidazolyles fongicides
EP2746256A1 (fr) 2012-12-19 2014-06-25 Basf Se Composés triazolyles et imidazolyles fongicides
EP2746277A1 (fr) 2012-12-19 2014-06-25 Basf Se Composés triazolyles et imidazolyles fongicides
WO2014095249A1 (fr) 2012-12-19 2014-06-26 Basf Se Composés d'imidazolyle et triazolyle fongicides
EP2746264A1 (fr) 2012-12-19 2014-06-25 Basf Se [1,2,4]triazole substitué et composés d'imidazole
EP2746255A1 (fr) 2012-12-19 2014-06-25 Basf Se Composés de [1,2,4]triazole et d'imidazole substitués
EP2746260A1 (fr) 2012-12-21 2014-06-25 Basf Se Composés de [1,2,4]triazole et d'imidazole substitués
EP2746259A1 (fr) 2012-12-21 2014-06-25 Basf Se Composés de [1,2,4]triazole et d'imidazole substitués
EP2746258A1 (fr) 2012-12-21 2014-06-25 Basf Se Composés de [1,2,4]triazole et d'imidazole substitués
EP2746257A1 (fr) 2012-12-21 2014-06-25 Basf Se Composés de [1,2,4]triazole et d'imidazole substitués
CN103058933B (zh) * 2012-12-29 2015-06-17 泉州师范学院 一种6-甲基-3-氨基哒嗪的工业化制备方法
JP6585625B2 (ja) 2014-01-21 2019-10-02 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 先天性副腎皮質過形成の処置のためのｃｒｆ１レセプターアンタゴニスト
JP6364967B2 (ja) * 2014-05-30 2018-08-01 東ソー株式会社 ジチエノベンゾジチオフェンの製造方法
TWI746426B (zh) 2014-11-16 2021-11-21 美商亞雷生物製藥股份有限公司 (S)-N-(5-((R)-2-(2,5-二氟苯基)-吡咯啶-1-基)-吡唑并[1,5-a]嘧啶-3-基)-3-羥基吡咯啶-1-甲醯胺硫酸氫鹽結晶型
RU2744852C2 (ru) 2015-10-26 2021-03-16 Локсо Онколоджи, Инк. Точечные мутации в устойчивых к ингибитору trk злокачественных опухолях и связанные с ними способы
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
WO2017176751A1 (fr) 2016-04-04 2017-10-12 Loxo Oncology, Inc. Formulations liquides de (s)-n-(5-((r)-2-(2,5-difluorophényl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
JP7443057B2 (ja) 2016-05-18 2024-03-05 ロクソ オンコロジー， インコーポレイテッド （Ｓ）－Ｎ－（５－（（Ｒ）－２－（２，５－ジフルオロフェニル）ピロリジン－１－イル）－ピラゾロ［１，５－ａ］ピリミジン－３－イル）－３－ヒドロキシピロリジン－１－カルボキサミドの調製
JP7117293B2 (ja) * 2016-09-16 2022-08-12 ヘルムホルツ ツェントゥルム ミュンヘン ドイチェス フォルシュングスツェントゥルム フューア ゲズントハイト ウント ウムヴェルト （ゲーエムベーハー） Ｔｒａｆ６阻害剤
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
KR102644781B1 (ko) * 2017-08-14 2024-03-06 스프루스 바이오사이언시스 인코포레이티드 코티코트로핀 방출 인자 수용체 길항제
EP4175572A4 (fr) 2020-08-12 2024-03-27 Spruce Biosciences Inc Procédés et compositions pour traiter le syndrome des ovaires polykystiques
CN113651762B (zh) * 2021-09-03 2023-12-26 上海晋鲁医药科技有限公司 一种1-甲基-1h-1,2,4-三氮唑-3-甲酸甲酯的制备方法
US11708372B2 (en) 2021-11-19 2023-07-25 Spruce Biosciences, Inc. Crystalline composition of tildacerfont and methods of use and preparation thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL191271B1 (pl) * 1996-02-07 2006-04-28 Neurocrine Biosciences Inc Pochodna pirazolopirymidyny i jej zastosowanie oraz kompozycja farmaceutyczna
US7105550B2 (en) * 2000-03-01 2006-09-12 Christopher Love 2,4-disubstituted thiazolyl derivatives
GB0017543D0 (en) * 2000-07-17 2000-09-06 Merck Sharp & Dohme Therapeutic agents
TWI312347B (en) * 2001-02-08 2009-07-21 Eisai R&D Man Co Ltd Bicyclic nitrogen-containing condensed ring compounds
TWI327462B (en) 2002-01-18 2010-07-21 Sumitomo Chemical Co Condensed heterocyclic sulfonyl urea compound, a herbicide containing the same, and a method for weed control using the same
JP4403105B2 (ja) * 2002-01-18 2010-01-20 住友化学株式会社 イミダゾピリダジン誘導体
JP2003313176A (ja) * 2002-04-24 2003-11-06 Sankyo Co Ltd アミノアゾール誘導体

Also Published As

Publication number Publication date
CR9389A (es) 2007-12-07
US20080113978A1 (en) 2008-05-15
CN101142217B (zh) 2010-12-08
JP4971300B2 (ja) 2012-07-11
ATE424402T1 (de) 2009-03-15
AU2006227300B2 (en) 2012-02-02
EA012393B1 (ru) 2009-10-30
CN101142217A (zh) 2008-03-12
PT1869049E (pt) 2009-05-26
EA200702044A1 (ru) 2008-02-28
CY1109069T1 (el) 2014-07-02
MX2007011600A (es) 2007-12-07
ZA200706715B (en) 2008-10-29
US7612067B2 (en) 2009-11-03
JP2008533201A (ja) 2008-08-21
CA2600478C (fr) 2013-02-05
DK1869049T3 (da) 2009-05-18
SI1869049T1 (sl) 2009-08-31
IL185014A0 (en) 2007-12-03
WO2006102194A1 (fr) 2006-09-28
AU2006227300A1 (en) 2006-09-28
DE602006005477D1 (en) 2009-04-16
ES2321446T3 (es) 2009-06-05
NO20074961L (no) 2007-10-17
TNSN07358A1 (en) 2008-12-31
PL1869049T3 (pl) 2009-07-31
CA2600478A1 (fr) 2006-09-28
BRPI0608857A2 (pt) 2012-08-28
KR20070120963A (ko) 2007-12-26
EP1869049B1 (fr) 2009-03-04
EP1869049A1 (fr) 2007-12-26

Similar Documents

Publication Publication Date Title
MA29437B1 (fr) Compose d'imidazopyridazine
MX2009003098A (es) Compuestos de tiofen pirazolopirimidina.
MX2009003125A (es) Tiazol pirazolopirimidinas como antagonistas de receptor de crf1.
ATE384050T1 (de) Benzazepinderivate als histamin-h3-antagonisten
MY161834A (en) Substituted diazepan compounds as orexin receptor antagonists
TW200621716A (en) Novel compounds
WO2005004818A3 (fr) Composes heterocycliques et leur utilisation comme agents anticancereux
WO2007025069A3 (fr) Diazaspirodecane utilise comme antagonistes de recepteurs d'orexine
MX2009005358A (es) Derivados de 5-sulfanilmetil-pirazolo[1,5-a]pirimidin-7-ol como antagonistas de cxcr2.
MA29623B1 (fr) Derives de pyrazolo [3, 4-d] azepine comme antagonistes d'histamine h3
TW200611701A (en) Novel compounds
DK1725536T3 (da) Imidazolin-derivater med CB1-antagonistisk aktivitet
WO2005075450A3 (fr) Nouveaux composes spiro-pentacycliques
EA200501595A1 (ru) Азабициклические производные в качестве антагонистов мускаринового рецептора
EA200501593A1 (ru) Азабициклические производные в качестве антагонистов мускаринового рецептора